ALG8 antibody
Principal name
ALG8 antibody
Alternative names for ALG8 antibody
Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase, Asparagine-linked glycosylation protein 8 homolog, Dol-P-Glc:Glc(1)Man(9)GlcNAc(2)-PP-dolichyl alpha-1,3-glucosyltransferase, Dolichyl-P-Glc:Glc1Man9GlcNAc2-PP-dolichyl glucosyltransferase
Ncbi ID
9606, NP_001029299.1, NP_076984.2, NP_950200.2, NM_199035, NM_001034127, NM_024079, NM_001007027
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Western blot / Immunoblot (WB), Paraffin Sections (P)
Background of ALG8 antibody
ALG8 adds the second glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation and transfers glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Glc1Man9GlcNAc(2)-PP-Dol. Defects in ALG8 are the cause of congenital disorder of glycosylation type 1H (CDG1H). CDGs are a family of severe inherited diseases caused by a defect in protein N-glycosylation. They are characterized by under-glycosylated serum proteins. These multisystem disorders present with a wide variety of clinical features, such as disorders of the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
General readings
"Clinical and molecular features of three patients with congenital disorders of glycosylation type Ih (CDG-Ih) (ALG8 deficiency)." Schollen E., Frank C.G., Keldermans L., Reyntjens R., Grubenmann C.E., Clayton P.T., Winchester B.G., Smeitink J., Wevers R.A., Aebi M., Hennet T., Matthijs G. J. Med. Genet. 41:550-556(2004)
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| TA323479 | ALG8 antibody |
||||||
| Anti-ALG8 Rabbit Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, P |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
 +1 additional image |
|||||||
Mouse Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| MR208441L2V | Lenti ORF particles, Alg8 (GFP-tagged) - Mouse asparagine-linked glycosylation 8 homolog (yeast, alpha-1,3-glucosyltransferase) (Alg8), 200 uL, >10^7 TU/mL |
|
 |
200 µl /
€1,220.00
|
|
| OriGene Technologies, Inc. | ||
| MR208441L1V | Lenti ORF particles, Alg8 (Myc-DDK-tagged) - Mouse asparagine-linked glycosylation 8 homolog (yeast, alpha-1,3-glucosyltransferase) (Alg8), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,090.00
|
|
| OriGene Technologies, Inc. | ||
Rat Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| RR214697L2V | Lenti ORF particles, Alg8 (GFP-tagged ORF) - Rat asparagine-linked glycosylation 8, alpha-1,3-glucosyltransferase homolog (S. cerevisiae) (Alg8), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,220.00
|
|
| OriGene Technologies, Inc. | ||
| RR214697L1V | Lenti ORF particles, Alg8 (Myc-DDK-tagged ORF) - Rat asparagine-linked glycosylation 8, alpha-1,3-glucosyltransferase homolog (S. cerevisiae) (Alg8), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,090.00
|
|
| OriGene Technologies, Inc. | ||